Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.16 +1.98 (+2.00%)
Official Closing Price Updated: 4:10 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
96 97 Next >
7 Safe Stocks to Steady Your Portfolio in 2024
With circumstances in the market applying the jitters, concerned investors may want to play these safe stocks to buy. 
Via InvestorPlace
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
From Merck & Co., Inc.
Via Business Wire
Merck's Lead Cancer Drug Meets Primary Goal In Certain Type Of Lung Cancer Patients
Merck & Co Inc (NYSE: MRK) reported topline data from the Phase 3 KEYNOTE-671 trial investigating Keytruda, Merck's anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable... 
Via Benzinga
Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for oncology and infectious disease and aging. 
Via Benzinga
Merck & Company Inc. (NYSE: MRK) Highlighted for Surprising Price Action
Via Investor Brand Network
9 Analysts Have This to Say About Merck & Co
Via Benzinga
How Is The Market Feeling About Merck & Co?
Via Benzinga
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
From Merck & Co., Inc.
Via Business Wire
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment. 
Via Talk Markets
3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI’
These are the AI stocks to buy and hold for multibagger returns in the next 24 months, as they represent quality growth companies. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth. 
Via MarketBeat
Disney Slashes Ticket Prices For Children, US Government Ceases Free Distribution Of Merck COVID Pill, UK Deep Dives Into Amazon And Microsoft's Cloud Power: Today's Top Stories
CNBC Disney Slashes Children's Ticket Prices Amid Attendance Slump 
Via Benzinga
Exposures COVID-19
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant... 
Via Benzinga
No Merck's COVID-19 Pill - US Government Ceases Free Distribution
The U.S. government is set to cease the distribution of free doses of Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral treatment Lagevrio (molnupiravir), by mid-November, shifting its availability to... 
Via Benzinga
Exposures COVID-19
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26
From Merck & Co., Inc.
Via Business Wire
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. 
Via Investor's Business Daily
Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares
3D Medicines Inc. was trading 7.2% higher in the Hong Kong Wednesday morning session at HK$5.53 after the company announced that it is buying back up to 10% of its own stock. 
Via Benzinga
2 Magnificent Growth Stocks to Buy Right Now
These two biotech stocks could be big winners for patient investors. 
Via The Motley Fool
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management... 
Via Benzinga
Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?
ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab) and paclitaxel for HER2-positive... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
These Market Experts See a Downturn Coming: 2 Defensive Index Funds That Are Proven Moneymakers to Buy Now
These defensive index funds can help investors hedge against a possible recession. 
Via The Motley Fool
Here's Why You Should Consider Moderna Stock, and No, It's Not the COVID Vaccine
The COVID-19 vaccine put Moderna on the map, but its pipeline is going to be what keeps it there. 
Via The Motley Fool
Exposures COVID-19
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amazon Web Services Now Offers Generative AI Tools For Businesses, Catches Up With Microsoft Azure, Google Cloud
Amazon is stepping into the generative AI arena with a new product called Bedrock, which offers its Amazon Web Services clients the use of generative AI tools. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation 
Via Benzinga
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
96 97 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.